Overview: Mitotane TestIntroduction: The Mitotane Test measures mitotane levels to monitor adrenal cancer treatment, preventing toxicity. Aligned with 2023 NCCN guidelines, it uses toxicology methods for high specificity, supporting drug monitoring. This test is critical for guiding treatment adjustments, preventing toxicity, and improving outcomes in oncology for patients receiving mitotane for adrenocortical carcinoma.
Other Names: Mitotane Assay, Adrenal Cancer Drug Test.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic accuracy.
Historical Milestone: Mitotane monitoring began in the 1960s with adrenal cancer research. Analytical methods improved in the 2000s, enhancing detection sensitivity.
Purpose: Measures mitotane levels to monitor adrenal cancer treatment, guides dosage adjustments, and prevents toxicity.
Test Parameters: 1. Mitotane Level
Pretest Condition: No fasting required. Collect serum or plasma. Report history of adrenal cancer, fatigue, or toxicity symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document adrenal cancer, fatigue, nausea, or neurological symptoms. Include current medications, especially mitotane or chemotherapy.
Consent: Written consent required, detailing the tests purpose, mitotane toxicity implications, and risks of blood collection.
Procedural Considerations: Uses toxicology methods (e.g., high-performance liquid chromatography) to measure mitotane levels in serum or plasma. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for adrenal cancer treatment monitoring.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Drug interactions may alter levels.
Clinical Significance: Elevated mitotane levels indicate risk of toxicity, guiding dose adjustment. Therapeutic levels support continued therapy.
Specialist Consultation: Consult an oncologist or endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: ACTH levels, cortisol levels, or adrenal imaging to monitor adrenal cancer treatment.
Test Limitations: Levels vary with dosing schedule; clinical correlation is needed. Sample timing affects accuracy.
References: NCCN Adrenal Cancer Guidelines, 2023; Journal of Clinical Oncology, Fassnacht M, 2022.
